A report released yesterday by the national consumer rights group Center for Justice and Democracy entitled “The Bitterest Pill – How Drugs Companies Fail to Protect Women and How Lawsuits Save Their Lives” revealed the devastating consequences that the regulatory failures and inadequacies of the FDA have had, specifically on women.
A recent article published by the Public Library of Science Medicine (PLoS Medicine), has highlighted new innovative ways in which pharmaceutical companies are promoting medications for off-label use.
The Bard® PerFix® Plug, introduced by Davol, Inc. and C.R. Bard, Inc., in 1993, is a medical device used to repair “primary and recurrent inguinal hernias.”
Pfizer has recently announced that it will "resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID)" pain medications Bextra and Celebrex, which Pfizer voluntarily withdrew from the U.S. market in 2005.
Just this week, the psoriasis drug Raptiva received a “black box” warning, the FDA’s strongest, regarding progressive multifocal leukoencephalopathy (PML) and other potentially fatal infections. Raptiva, manufactured by Genentech, is a medication given via weekly injection to treat moderate to severe plaque psoriasis in adults only. Raptiva is a biologic drug that works to suppress the immune system with the goal of fewer psoriasis flare-ups. However, as with any immunosuppressant, the use of Raptiva compromises the immune system to such an extent that it increases the risks of serious infections, some fatal, and other malignancies.
We would like to extend a special thank you to our friends at the American Association of Justice (formerly, the Association of Trial Lawyers of America), which yesterday published a comprehensive and thoroughly illuminating report examining the Bush Administration's preemption agenda during the last eight years. This is an excellent piece of work, and a must read for every plaintiff's lawyer. We won't belabor this blog spot with commentary (and there's not much we could add anyway), but instead let you get right to reading it ... AAJ Preemption Report.
In newly filed court documents, evidence has surfaced showing that top marketing executives from Pfizer "suppressed a large European study suggesting their blockbuster medication Neurontin was ineffective for chronic nerve pain."
On September 26, 2008, the FDA issued a Class-1 Recall of all Medtronic Neuromodulation INDURA One-Piece (IP) Intrathecal Catheters.
Not all managers are exempt from getting paid time and a half for those hours worked over forty in a week. While the Fair Labor Standards Act (FLSA) does have an “executive” exemption, not all managers are necessarily covered by the exemption. However, many employers simply assume that the exemption applies without any real analysis. Under the exemption, there are very specific criteria outlined that need to be satisfied in order for a manager, supervisor, or other executive position to fall within the exemption.